Innova Captab Limited (INNOVACAP) Q2 FY27 Financial Results: PAT ₹403.49 Cr & Revenue ₹4,493.66 Cr

Investor Takeaways

• Revenue of ₹4493.66 Cr reported for FY26, up from ₹262.63 Cr in Q4FY24, indicating growth from ₹262.63 Cr to ₹4493.66 Cr YoY.
• Net Profit of ₹403.49 Cr for FY26, compared to ₹28.72 Cr in Q4FY24, reflecting an increase from ₹28.72 Cr to ₹403.49 Cr YoY.
• OPM of 14.71% in Q3FY25, with no material change noted in profitability trends across quarters.
• ₹45 Cr brownfield expansion approved in Baddi, Himachal Pradesh, to enhance manufacturing capacity, financed through bank credit and internal accruals.
• Interim dividend of ₹2 per share declared, consistent with prior shareholder returns.
• Auditor issued unmodified opinion on revised FY26 results, confirming compliance with SA 560 and SEBI guidelines.
• Revisions to prior periods were limited to identified errors with no material impact on profit, equity, or assets.

Overall Tone: Neutral

Key Financial Highlights

What Changed

The filing confirms that Innova Captab Limited approved revised audited financial results for FY26, correcting previously reported figures due to adjustments in deferred tax assets, supplier finance reclassification, and cash flow restatements. These revisions were non-material, with no impact on profit, equity, or assets. Revenue for FY26 stood at ₹4493.66 Cr, up from ₹262.63 Cr in the previous quarter (Q4FY24), and net profit increased to ₹403.49 Cr from ₹28.72 Cr in Q4FY24. The company also approved a ₹45 Cr expansion in Baddi, Himachal Pradesh, to scale manufacturing operations, funded through bank credit and internal accruals. The board approved the revised financials and expansion plan on 22 August 2026. The auditor’s unmodified opinion validates the accuracy of the revised figures under SA 560 and SEBI guidelines. No new risks or material changes were disclosed. The company maintained its interim dividend of ₹2 per share. The growth in revenue and profit reflects operational expansion, though capital allocation for the expansion requires monitoring.

Peer Comparison

Innova Captab’s P/E ratio of 38.56 is lower than Sun Pharmaceutical (41.28) and significantly lower than Divi's Laboratories (72.41) and Torrent Pharmaceuticals (80.06), suggesting relatively moderate valuation compared to peers.

Innova Captab Limited operates in the Healthcare | Pharmaceuticals & Biotechnology sector, with a Market Cap of ₹4,911.62 Cr, placing it smaller than Sun Pharmaceutical (₹4,50,643.09 Cr) but larger than Divi's Laboratories (₹1,79,470.03 Cr) and Torrent Pharmaceuticals (₹1,49,108.91 Cr) in terms of market capitalization.

Comparison: Innova Captab’s valuation metrics are more conservative than larger peers, but its growth trajectory and expansion plans position it in a competitive segment of the pharmaceutical industry.

Risks & Concerns

• No specific risks identified in this filing.
• Capital allocation for the ₹45 Cr expansion will require monitoring for execution efficiency and return on investment.

Quarterly Trend